

**EU Risk Management Plan**  
**for**  
**Icatibant Accord 30 mg solution for injection in pre-filled syringe**  
**(Icatibant)**

**RMP version to be assessed as part of this application:**

RMP Version number	2.0
Data lock point for this RMP	30-Oct-2025
Date of final sign off	16-Jan-2026

**Rationale for submitting an updated RMP:** This Risk Management Plan (RMP) has been updated in line with European Public Assessment Report (EPAR) RMP of reference product Firazyr (Icatibant) (version 8.1, dated 20-Jun-2025) published on EMA website on 15-Oct-2025.

**Summary of significant changes in this RMP:** Significant changes have been made in following sections of RMP: Part I, Part II (Module SVII and SVIII), Part III (III.1 and III.2), Part VI and Part VII (Annex 1, 7 and 8).

**Other RMP versions under evaluation:** Not applicable

**Details of the currently approved RMP:**

Version	Approved with procedure	Date of approval (opinion date)
1.1	EMEA/H/C/005083	20-May-2021

**QPPV Name:** Dr. Arletta Werynska

**QPPV Signature:**



## TABLE OF CONTENTS

<b>TABLE OF CONTENTS</b> .....	<b>3</b>
<b>LIST OF TABLES</b> .....	<b>5</b>
<b>Part I: Products Overview</b> .....	<b>6</b>
<b>Part II: Safety specification</b> .....	<b>10</b>
Part II: Module SI – Epidemiology of the indication(s) and target population(s) .....	10
Part II: Module SII – Non-clinical part of the safety specification.....	10
Part II: Module SIII – Clinical trial exposure .....	10
Part II: Module SIV – Populations not studied in clinical trials .....	10
SIV.1 Exclusion criteria in pivotal clinical studies within the development programme.....	10
SIV.2 Limitations to detect adverse reactions in clinical trial development programmes.....	10
SIV.3 Limitations in respect to populations typically under-represented in clinical trial development programmes.....	10
Part II: Module SV – Post-authorisation experience .....	10
SV.1 Post-authorisation exposure.....	10
Part II: Module SVI – Additional EU requirements for the safety specification.....	10
Part II: Module SVII – Identified and potential risks .....	11
SVII.1 Identification of safety concerns in the initial RMP submission.....	11
SVII.1.1 Risks not considered important for inclusion in the list of safety concerns in the RMP.....	11
SVII.1.2 Risks considered important for inclusion in the list of safety concerns in the RMP.....	11
SVII.2 New safety concerns and reclassification with a submission of an updated RMP.....	11
SVII.3 Details of important identified risks, important potential risks, and missing information.....	11
SVII.3.1 Presentation of important identified risks and important potential risks.....	11
SVII.3.2 Presentation of the missing information.....	11
Part II: Module SVIII – Summary of the safety concerns .....	12
<b>Part III: Pharmacovigilance Plan (including post-authorisation safety studies)</b> .....	<b>13</b>
III.1 Routine pharmacovigilance activities.....	13
III.2 Additional pharmacovigilance activities .....	13
III.3 Summary Table of additional Pharmacovigilance activities .....	13
<b>Part IV: Plans for post-authorisation efficacy studies</b> .....	<b>14</b>
<b>Part V: Risk minimisation measures (including evaluation of the effectiveness of risk minimisation activities)</b> .....	<b>15</b>
V.1 Routine Risk Minimisation Measures .....	15
V.2 Additional Risk Minimisation Measures .....	15
V.3 Summary of risk minimisation measures .....	15

**Part VI: Summary of the risk management plan ..... 16**

I. The medicine and what it is used for..... 16

II. Risks associated with the medicine and activities to minimise or further characterise the risks ..... 17

    II.A List of important risks and missing information ..... 17

    II.B Summary of important risks ..... 18

    II.C Post-authorisation development plan..... 18

        II.C.1 Studies which are conditions of the marketing authorisation ..... 18

        II.C.2 Other studies in post-authorisation development plan..... 18

**Part VII: Annexes..... 19**

Annex 1 – EudraVigilance Interface..... 20

Annex 2 – Tabulated summary of planned, ongoing, and completed pharmacovigilance study programme..... 20

Annex 3 – Protocols for proposed, on-going and completed studies in the pharmacovigilance plan ..... 20

Annex 4 – Specific adverse drug reaction follow-up forms ..... 20

Annex 5 – Protocols for proposed and on-going studies in RMP part IV ..... 20

Annex 6 – Details of proposed additional risk minimisation activities (if applicable)..... 20

Annex 7 – Other supporting data (including referenced material) ..... 20

Annex 8 – Summary of changes to the risk management plan over time..... 20



**LIST OF TABLES**

Table 1: Product Overview..... 6  
Table 2: Summary of safety concerns ..... 12



## Part I: Products Overview

Table 1: Product Overview

<b>Active substance(s) (INN or common name)</b>	Icatibant
<b>Pharmacotherapeutic group(s) (ATC Code)</b>	<b>Pharmacotherapeutic group(s):</b> Other haematological agents, drugs used to treat hereditary angioedema  <b>ATC code:</b> B06AC02
<b>Marketing Authorisation Holder</b>	Accord Healthcare S.L.U, Spain
<b>Medicinal products to which this RMP refers</b>	1
<b>Invented name(s) in the European Economic Area (EEA)</b>	Icatibant Accord 30 mg solution for injection in pre-filled syringe
<b>Marketing authorisation procedure</b>	Centralised Procedure: EMEA/H/C/005083
<b>Brief description of the product</b>	<p><b><u>Chemical class:</u></b></p> <p>Icatibant is a selective competitive antagonist at the bradykinin type 2 (B2) receptor. It is a synthetic decapeptide with a structure similar to bradykinin, but with 5 non-proteinogenic amino acids.</p> <p><b><u>Summary of mode of action:</u></b></p> <p>HAE (Hereditary Angioedema, an autosomal dominant disease) is caused by an absence or dysfunction of C1-esterase-inhibitor. HAE attacks are accompanied by an increased release of bradykinin, which is the key mediator in the development of the clinical symptoms.</p>

	<p>HAE manifests as intermittent attacks of subcutaneous and/or sub mucosal oedema involving the upper respiratory tract, the skin and the gastrointestinal tract. An attack usually lasts between 2 to 5 days.</p> <p>Icatibant is a selective competitive antagonist at the bradykinin type 2 (B2) receptor. It is a synthetic decapeptide with a structure similar to bradykinin, but with 5 non-proteinogenic amino acids. In HAE increased bradykinin concentrations are the key mediator in the development of the clinical symptoms.</p>
	<p><b><u>Important information about its composition</u></b></p> <p><i><u>Icatibant Accord 30 mg solution for injection in pre-filled syringe</u></i></p> <p>Each pre-filled syringe of 3 ml contains icatibant acetate equivalent to 30 mg icatibant.</p> <p>Each ml of the solution contains 10 mg of icatibant.</p>
<p><b>Hyperlink to the Product Information</b></p>	<p>Refer <a href="#">Module 1.3.1</a> for Product Information</p>
<p><b>Indications in the EEA</b></p>	<p><b><i>Current:</i></b></p> <p>Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.</p>
<p><b>Dosage in the EEA</b></p>	<p><b><i>Current:</i></b></p> <p><b><u>Posology</u></b></p> <p><b><u>Adults:</u></b></p> <p>The recommended dose for adults is a single subcutaneous injection of Icatibant Accord 30 mg.</p> <p>In the majority of cases a single injection of Icatibant Accord is sufficient to treat an attack. In case of insufficient relief or</p>

recurrence of symptoms, a second injection of Icatibant Accord can be administered after 6 hours. If the second injection produces insufficient relief or a recurrence of symptoms is observed, a third injection of Icatibant Accord can be administered after a further 6 hours. No more than 3 injections of Icatibant Accord should be administered in a 24-hour period.

In the clinical trials, not more than 8 injections of Icatibant Accord per month have been administered.

Paediatric population:

The recommended dose of Icatibant Accord based on body weight in children and adolescents (aged 2 to 17 years) is provided in table below.

Body Weight	Dose (Injection Volume)
12 kg to 25 kg	10 mg (1.0 ml)
26 kg to 40 kg	15 mg (1.5 ml)
41 kg to 50 kg	20 mg (2.0 ml)
51 kg to 65 kg	25 mg (2.5 ml)
>65 kg	30 mg (3.0 ml)

In the clinical trial, not more than 1 injection of Icatibant Accord per HAE attack has been administered.

No dosage regimen for children aged less than 2 years or weighing less than 12 kg can be recommended as the safety and efficacy in this paediatric group has not been established.

**Method of administration:**

Icatibant Accord is intended for subcutaneous administration, preferably in the abdominal area.

	<p>Icatibant Accord solution for injection should be injected slowly due to the volume to be administered.</p> <p>Each Icatibant Accord syringe is intended for single use only.</p>
<p><b>Pharmaceutical forms and strengths</b></p>	<p><i>Current:</i></p> <p><b>Pharmaceutical form:</b> Solution for injection</p> <p><b>Strength:</b> 30 mg (10 mg/ml)</p>
<p><b>Is the product subject to additional monitoring in the EU?</b></p>	<p>No</p>



**Part II: Safety specification**

**Part II: Module SI – Epidemiology of the indication(s) and target population(s)**

Not applicable

**Part II: Module SII – Non-clinical part of the safety specification**

Not applicable

**Part II: Module SIII – Clinical trial exposure**

Not applicable

**Part II: Module SIV – Populations not studied in clinical trials**

**SIV.1 Exclusion criteria in pivotal clinical studies within the development programme**

Not applicable

**SIV.2 Limitations to detect adverse reactions in clinical trial development programmes**

Not applicable

**SIV.3 Limitations in respect to populations typically under-represented in clinical trial development programmes**

Not applicable

**Part II: Module SV – Post-authorisation experience**

**SV.1 Post-authorisation exposure**

Not applicable

**Part II: Module SVI – Additional EU requirements for the safety specification**

**SVI.1 Potential for misuse for illegal purposes**

Not applicable



**Part II: Module SVII – Identified and potential risks**

The safety concerns for this RMP have been updated in line with EPAR- RMP of reference product Firazyr (Icatibant) (version 8.1, dated 20-Jun-2025) published on EMA website on 15-Oct-2025. There is no change proposed by MAH in the safety concern mentioned in Module SVIII. Hence, this section remains “Not applicable”.

**SVII.1 Identification of safety concerns in the initial RMP submission**

**SVII.1.1 Risks not considered important for inclusion in the list of safety concerns in the RMP**

Not applicable

**SVII.1.2 Risks considered important for inclusion in the list of safety concerns in the RMP**

Not applicable

**SVII.2 New safety concerns and reclassification with a submission of an updated RMP**

Not applicable

**SVII.3 Details of important identified risks, important potential risks, and missing information**

**SVII.3.1 Presentation of important identified risks and important potential risks**

Not applicable

**SVII.3.2 Presentation of the missing information**

Not applicable

**Part II: Module SVIII – Summary of the safety concerns**

**Table 2: Summary of safety concerns**

Important identified risk	<ul style="list-style-type: none"><li>• None</li></ul>
Important potential risk	<ul style="list-style-type: none"><li>• None</li></ul>
Missing information	<ul style="list-style-type: none"><li>• Use in pregnant and lactating women</li></ul>



### **Part III: Pharmacovigilance Plan (including post-authorisation safety studies)**

#### **III.1 Routine pharmacovigilance activities**

Routine pharmacovigilance activities including collection and reporting of adverse reactions and signal detection as stated in pharmacovigilance system master file are sufficient for the mentioned safety concern.

#### **Specific adverse reaction follow-up questionnaires for safety concern:**

None

#### **Other forms of routine pharmacovigilance activities for safety concern:**

None

#### **III.2 Additional pharmacovigilance activities**

None proposed.

#### **III.3 Summary Table of additional Pharmacovigilance activities**

Not applicable



**Part IV: Plans for post-authorisation efficacy studies**

Not applicable



**Part V: Risk minimisation measures (including evaluation of the effectiveness of risk minimisation activities)**

**Risk Minimisation Plan**

The safety information in the proposed product information is aligned to the reference medicinal product.

**V.1 Routine Risk Minimisation Measures**

Not applicable

**V.2 Additional Risk Minimisation Measures**

None proposed

**V.3 Summary of risk minimisation measures**

Not applicable



**Part VI: Summary of the risk management plan****Summary of risk management plan for Icatibant Accord 30 mg solution for injection in pre-filled syringe (Icatibant)**

This is a summary of the risk management plan (RMP) for Icatibant Accord 30 mg solution for injection in pre-filled syringe. The RMP details important risks of Icatibant Accord 30 mg solution for injection in pre-filled syringe, how these risks can be minimised, and how more information will be obtained about Icatibant Accord 30 mg solution for injection in pre-filled syringe risks and uncertainties (missing information).

Icatibant Accord 30 mg solution for injection in pre-filled syringe's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Icatibant Accord 30 mg solution for injection in pre-filled syringe should be used.

This summary of the RMP for Icatibant Accord 30 mg solution for injection in pre-filled syringe should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Icatibant Accord 30 mg solution for injection in pre-filled syringe's RMP.

**I. The medicine and what it is used for**

Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.

It contains Icatibant as the active substance and it is administered by subcutaneous route.

Further information about the evaluation of Icatibant Accord 30 mg solution for injection in pre-filled syringe's benefits can be found in Icatibant Accord 30 mg solution for injection in pre-filled syringe's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage.

<https://www.ema.europa.eu/en/medicines/human/EPAR/icatibant-accord>

## II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Icatibant Accord 30 mg solution for injection in pre-filled syringe, together with measures to minimise such risks and the proposed studies for learning more about Icatibant Accord 30 mg solution for injection in pre-filled syringe's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation measures*.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Icatibant Accord 30 mg solution for injection in pre-filled syringe is not yet available, it is listed under 'missing information' below.

### II.A List of important risks and missing information

Important risks of Icatibant Accord 30 mg solution for injection in pre-filled syringe are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Icatibant Accord 30 mg solution for injection in pre-filled syringe. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on

the long-term use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risk	<ul style="list-style-type: none"> <li>• None</li> </ul>
Important potential risk	<ul style="list-style-type: none"> <li>• None</li> </ul>
Missing information	<ul style="list-style-type: none"> <li>• Use in pregnant and lactating women</li> </ul>

**II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

**II.C Post-authorisation development plan**

**II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorization or specific obligation of Icatibant Accord 30 mg solution for injection in pre-filled syringe.

**II.C.2 Other studies in post-authorisation development plan**

There are no studies required for Icatibant Accord 30 mg solution for injection in pre-filled syringe as post-authorisation development plan.

